PST1 Antibody

What is PST1 and why are PST1 antibodies important in research?

PST1 is an alias name for ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4, a 359-amino acid protein encoded by the ST8SIA4 gene in humans. This enzyme catalyzes the polycondensation of alpha-2,8-linked sialic acid required for polysialic acid (PSA) synthesis, which is crucial for neural cell adhesion molecule (N-CAM) function and neural plasticity. PST1 is localized to the Golgi apparatus and features glycosylated post-translational modifications. It shows high expression in fetal brain, lung, and kidney tissues, as well as adult heart, spleen, and thymus .

Antibodies against PST1 are valuable research tools for studying its expression, localization, and function in both normal physiological processes and disease states. They enable scientists to investigate the role of this enzyme in neural development, immune function, and potentially in pathological conditions where aberrant glycosylation occurs.

What are the primary applications for PST1 antibodies in laboratory research?

The most common applications for PST1 antibodies include:

• Western Blot (WB): For detecting PST1 protein in tissue or cell lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of PST1 levels

• Immunohistochemistry (IHC): For visualizing PST1 distribution in tissue sections

• Immunofluorescence (IF): For subcellular localization studies, particularly in Golgi apparatus

• Immunoprecipitation (IP): For isolating PST1 and associated protein complexes

When designing experiments, researchers should be aware that application-specific validation is essential, as antibody performance can vary significantly between different experimental contexts.

How should researchers select the appropriate PST1 antibody for their specific experiment?

Selection of the appropriate PST1 antibody depends on several critical factors:

When studying human ST8SIA4, researchers should be careful not to confuse it with yeast Pst1, which is a completely different 444-amino acid protein involved in cell wall construction .

What are the recommended storage and handling conditions for PST1 antibodies?

To maintain antibody integrity and performance, researchers should adhere to these storage and handling guidelines:

• Storage temperature: Most PST1 antibodies should be stored at -20°C for long-term stability. Some formulations with glycerol (50%) can be stored at -20°C without aliquoting .

• Buffer composition: Typical storage buffers include PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Aliquoting: For antibodies without glycerol, prepare small aliquots to avoid repeated freeze-thaw cycles that can diminish activity.

• Thawing procedure: Thaw antibodies on ice or at 4°C rather than at room temperature.

• Working dilutions: Prepare fresh working dilutions on the day of the experiment, as diluted antibodies lose activity over time.

• Contamination prevention: Use sterile technique when handling antibodies to prevent microbial contamination.

• Expiration: Most manufacturers indicate stability for one year after shipment when stored properly .

What methods should be used to validate the specificity of PST1 antibodies?

Rigorous validation of PST1 antibody specificity is essential for reliable research outcomes. Recommended validation strategies include:

• Positive and negative control tissues/cells: Compare tissues known to express high levels of ST8SIA4 (fetal brain, thymus, spleen) with tissues showing minimal expression.

• Knockdown/knockout verification: Use CRISPR/Cas9 or siRNA approaches to create ST8SIA4 knockdown/knockout samples and confirm signal reduction or elimination.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application to verify signal elimination.

• Multiple antibody validation: Confirm results using at least two different antibodies targeting distinct epitopes of ST8SIA4.

• Mass spectrometry correlation: Confirm antibody-detected protein identity through immunoprecipitation followed by mass spectrometry.

• Cross-reactivity testing: Test against related sialyltransferases (ST8SIA2, ST8SIA3) to ensure specificity.

• Molecular weight verification: Confirm the detected protein migrates at the expected molecular weight (approximately 41 kDa calculated, though glycosylation often results in higher apparent molecular weight) .

What are the optimal protocols for using PST1 antibodies in Western blot applications?

Optimized Western blot protocol for PST1/ST8SIA4 detection:

• Sample preparation:

  • Extract proteins using RIPA buffer containing protease inhibitors

  • Include 1% NP-40 or Triton X-100 to help solubilize membrane-associated proteins

  • Heat samples at 70°C (not 95°C) for 10 minutes to minimize aggregation of glycosylated proteins

• Gel electrophoresis:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Load 20-50 μg of total protein per lane

  • Include positive control (e.g., fetal brain lysate)

• Transfer conditions:

  • Semi-dry or wet transfer at 25V for 1.5 hours

  • Use PVDF membrane (preferred over nitrocellulose for glycoproteins)

• Blocking:

  • 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Alternatively, 3% BSA in TBST if using phospho-specific antibodies

• Primary antibody incubation:

  • Dilute antibody 1:500 to 1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

• Detection considerations:

  • Expected molecular weight: Calculated 41 kDa, but often appears higher (50-60 kDa) due to glycosylation

  • For yeast Pst1 studies, note that wild-type Pst1 migrates at approximately 200 kDa, while mutant forms may appear at 100 kDa

• Signal enhancement:

  • Consider using enhanced chemiluminescence (ECL) substrate for optimal sensitivity

  • Longer exposure times may be necessary for low abundance samples

How do post-translational modifications affect PST1 antibody detection?

Post-translational modifications significantly impact PST1/ST8SIA4 antibody detection due to the protein's extensive glycosylation:

• Effect on epitope accessibility: Glycosylation can mask epitopes and prevent antibody binding, especially for antibodies targeting regions near glycosylation sites.

• Molecular weight variability: The calculated molecular weight of ST8SIA4 is 41 kDa, but due to glycosylation, it typically migrates at higher apparent molecular weights on SDS-PAGE .

• Tissue-specific glycosylation patterns: The extent and pattern of glycosylation may vary between tissues, potentially affecting antibody recognition.

• Deglycosylation strategies: For consistent detection, researchers can use:

  • PNGase F treatment to remove N-linked glycans

  • Neuraminidase to remove sialic acid residues

  • O-glycosidase for O-linked glycans

• Yeast Pst1 considerations: When studying yeast Pst1, note that it contains 15 potential N-linked glycosylation sites and migrates at approximately 200 kDa in wild-type S. cerevisiae but at 100 kDa in triple-mutant strains with altered glycosylation patterns .

• Comparison table of glycosylation effects on detection:

What are the considerations when using PST1 antibodies for immunohistochemistry or immunofluorescence?

When performing IHC or IF with PST1 antibodies, researchers should consider these technical aspects:

• Fixation methods:

  • 4% paraformaldehyde is generally preferred for preserving protein structure

  • Avoid methanol fixation which can disrupt glycoprotein epitopes

  • Limit fixation time to preserve antigenicity

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) is recommended

  • For formalin-fixed paraffin-embedded tissues, retrieval is critical due to cross-linking

• Expected localization pattern:

  • Primary localization in Golgi apparatus

  • Potential punctate perinuclear staining pattern

  • Co-staining with Golgi markers (GM130, TGN46) recommended for verification

• Background reduction:

  • Extensive blocking (3% BSA, 10% normal serum from secondary antibody host species)

  • Pre-adsorption of antibody with tissue powder from negative control samples

  • Include 0.1-0.3% Triton X-100 for intracellular antigens

• Controls:

  • Positive tissue controls: fetal brain, adult thymus, spleen

  • Negative controls: samples known to lack ST8SIA4 expression

  • Technical controls: primary antibody omission, isotype controls

• Signal amplification:

  • Tyramide signal amplification can enhance detection of low-abundance antigens

  • Avoid excessive amplification which can increase background

• Co-localization studies:

  • Pair with antibodies against polysialic acid (PSA) to study functional relationships

  • Use confocal microscopy for precise co-localization assessment

How can PST1 antibodies be used to study polysialic acid synthesis pathways?

PST1/ST8SIA4 antibodies are valuable tools for investigating polysialic acid synthesis pathways through these methodological approaches:

• Enzyme activity correlation studies:

  • Immunoprecipitate ST8SIA4 using specific antibodies

  • Perform in vitro sialyltransferase assays using the immunoprecipitate

  • Correlate protein levels (detected by antibodies) with enzymatic activity

• Regulatory pathway investigation:

  • Use PST1 antibodies in conjunction with pharmacological inhibitors or activators

  • Monitor changes in ST8SIA4 levels in response to pathway modulators

  • Combine with phospho-specific antibodies to study regulatory post-translational modifications

• Developmental expression profiling:

  • Apply antibodies to tissues at different developmental stages

  • Correlate ST8SIA4 expression with polysialic acid levels (using anti-PSA antibodies)

  • Use tissue microarrays for high-throughput analysis

• Co-immunoprecipitation for protein interaction studies:

  • Use PST1 antibodies to pull down protein complexes

  • Identify interacting partners through Western blot or mass spectrometry

  • Validate physiological relevance of interactions through functional assays

• Subcellular fractionation validation:

  • Use PST1 antibodies to track the protein across subcellular fractions

  • Combine with markers for Golgi and transport vesicles

  • Study trafficking between compartments during PSA synthesis

• In vivo models:

  • Correlate antibody-detected ST8SIA4 levels with functional outcomes in knockout/knockin models

  • Use tissue-specific conditional knockout models to pinpoint ST8SIA4 function

What are the common issues and troubleshooting strategies when working with PST1 antibodies?

How do research applications differ between human ST8SIA4 antibodies and yeast Pst1 antibodies?

The applications and considerations for human ST8SIA4 antibodies versus yeast Pst1 antibodies differ significantly, as they target entirely different proteins with distinct functions:

What protocols are recommended for analyzing PST1 expression in clinical samples?

For clinical sample analysis of PST1/ST8SIA4 expression, researchers should consider these methodological approaches:

• Tissue processing and preservation:

  • Flash freezing in liquid nitrogen for RNA and protein extraction

  • Formalin fixation (10% neutral buffered formalin, 24h) for paraffin embedding

  • OCT embedding for frozen sections

• RNA expression analysis:

  • RT-qPCR with validated primers spanning exon junctions

  • RNAscope® for in situ hybridization with spatial resolution

  • RNA-seq with specific attention to splice variants

• Protein extraction from clinical samples:

  • RIPA buffer with protease inhibitor cocktail for total protein

  • Membrane fraction enrichment for better detection

  • Avoid repeated freeze-thaw cycles

• Immunohistochemistry protocol for FFPE tissues:

  • Deparaffinization and rehydration

  • Heat-induced epitope retrieval: 20 minutes in citrate buffer (pH 6.0)

  • Blocking: 10% normal serum, 1% BSA, 0.1% Tween-20 in TBS

  • Primary antibody incubation: 1:100-1:500 dilution, overnight at 4°C

  • Detection: HRP-polymer and DAB chromogen system

  • Counterstain: Mayer's hematoxylin

  • Controls: Include brain tissue as positive control

• Scoring and quantification methods:

  • H-score: combines intensity (0-3) and percentage of positive cells

  • Digital image analysis for objective quantification

  • Correlation with clinical parameters and outcomes

• Multi-parameter analysis:

  • Multiplex immunofluorescence to correlate with other markers

  • Combined analysis of PST1 and polysialic acid levels

  • Integration with genomic and transcriptomic data

How can PST1 antibodies be used in studying neurological development and disorders?

PST1/ST8SIA4 plays a crucial role in neural plasticity through its involvement in polysialic acid synthesis on NCAM. Researchers investigating neurological development and disorders can use PST1 antibodies in these methodological approaches:

• Developmental timing studies:

  • Track ST8SIA4 expression across developmental stages using immunohistochemistry

  • Correlate with neuronal migration and axon pathfinding events

  • Compare expression in different brain regions during critical periods

• Neuronal plasticity experiments:

  • Assess ST8SIA4 levels in learning and memory paradigms

  • Study expression changes following injury or environmental enrichment

  • Correlate with functional recovery after trauma

• Neurological disorder investigations:

  • Compare ST8SIA4 expression in control vs. disorder tissue samples

  • Analyze potential alterations in schizophrenia, autism spectrum disorders, and epilepsy

  • Correlate with abnormal neuronal migration or connectivity

• In vitro neural differentiation models:

  • Monitor ST8SIA4 expression during differentiation of neural stem cells

  • Manipulate expression levels to study effects on neurite outgrowth

  • Co-stain with neuronal markers to correlate with maturation stages

• Therapeutic target assessment:

  • Use antibodies to validate target engagement in drug development

  • Monitor expression changes in response to experimental therapeutics

  • Develop companion diagnostics for treatments targeting this pathway

What considerations are important when using PST1 antibodies in cancer research?

Cancer researchers investigating ST8SIA4/PST1 should consider these methodological approaches and technical considerations:

• Expression profiling across cancer types:

  • Use tissue microarrays with PST1 antibodies to screen multiple cancer types

  • Correlate expression with clinical outcomes and metastatic potential

  • Compare with normal adjacent tissue controls

• Relationship to immune evasion:

  • Investigate ST8SIA4 expression in relation to immune cell infiltration

  • Study potential roles in modulating immune checkpoint molecules

  • Assess impact on natural killer cell recognition

• Cell line validation considerations:

  • Verify antibody specificity in cancer cell lines with known ST8SIA4 expression

  • Use multiple antibody clones to confirm expression patterns

  • Consider the impact of in vitro culture conditions on expression levels

• Metastasis mechanisms investigation:

  • Compare primary tumors versus metastatic lesions for ST8SIA4 expression

  • Correlate with cell adhesion molecule modifications

  • Study impact on cell migration and invasion in functional assays

• Therapeutic response monitoring:

  • Assess changes in ST8SIA4 expression following treatment

  • Investigate potential as a predictive biomarker for specific therapies

  • Study in patient-derived xenograft models for translational relevance

• Technical considerations for cancer tissue analysis:

  • Account for tumor heterogeneity by analyzing multiple regions

  • Use laser capture microdissection for pure tumor cell populations

  • Include appropriate controls for antibody validation in each experiment

How can researchers optimize immunoprecipitation protocols for PST1/ST8SIA4?

Optimized immunoprecipitation protocol for PST1/ST8SIA4:

• Buffer selection and cell lysis:

  • Use NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8.0)

  • Add protease inhibitors (PMSF, leupeptin, aprotinin)

  • Include 1 mM sodium orthovanadate and 10 mM sodium fluoride as phosphatase inhibitors

  • Lyse cells on ice for 30 minutes with gentle agitation

• Pre-clearing:

  • Incubate lysate with protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation (1000 × g, 5 minutes)

  • This step reduces non-specific binding

• Antibody binding:

  • Use 2-5 μg of PST1 antibody per 500 μg of total protein

  • Incubate overnight at 4°C with gentle rotation

  • For polyclonal antibodies, longer incubation improves binding

• Immune complex capture:

  • Add pre-washed protein A/G beads (40 μl of 50% slurry)

  • Incubate for 3-4 hours at 4°C with gentle rotation

  • Collect beads by gentle centrifugation (1000 × g, 5 minutes)

• Washing procedure:

  • Wash 4-5 times with cold lysis buffer

  • Use final wash with PBS to remove detergent

  • Keep samples cold throughout to minimize protein degradation

• Elution strategies:

  • Harsh elution: Boil in 2× Laemmli buffer (with β-mercaptoethanol) at 70°C for 10 minutes

  • Gentle elution: Use acidic glycine buffer (0.1 M glycine, pH 2.5) followed by neutralization

  • Native elution: Use excess immunizing peptide if available

• Controls and validation:

  • IgG control: Parallel IP with isotype-matched control antibody

  • Input control: Save 5% of pre-IP lysate for comparison

  • Verification: Confirm successful IP by Western blot with a different PST1 antibody

What are the considerations for multiplexing PST1 antibodies with other glycosylation markers?

When multiplexing PST1/ST8SIA4 antibodies with other glycosylation markers, researchers should consider:

• Antibody compatibility planning:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • Verify that secondary antibodies do not cross-react with primary antibodies

  • Test each antibody individually before multiplexing

• Recommended marker combinations:

  • PST1 with polysialic acid (PSA) antibodies to correlate enzyme with product

  • PST1 with other sialyltransferases (ST8SIA2/STX) for pathway analysis

  • PST1 with Golgi markers (GM130, TGN46) for localization studies

  • PST1 with NCAM to study the enzyme-substrate relationship

• Staining sequence optimization:

  • Sequential staining may be necessary if antibodies require different fixation/retrieval

  • Consider tyramide signal amplification for low-abundance antigens

  • Include spectral unmixing steps for fluorescence multiplexing

• Detection strategy selection:

  • Chromogenic multiplex IHC: Requires careful optimization of substrate colors

  • Fluorescence multiplex: Allows for more markers but needs spectral separation

  • Mass cytometry (CyTOF): For highest multiplexing capacity with metal-conjugated antibodies

• Controls for multiplexed experiments:

  • Single-stained controls for each marker

  • Fluorescence minus one (FMO) controls

  • Absorption controls to verify antibody specificity

• Analysis considerations:

  • Colocalization analysis metrics (Pearson's, Mander's coefficients)

  • Cell-by-cell quantification of multiple markers

  • Spatial relationship mapping between different glycosylation components

How should researchers interpret differences in PST1 antibody signal across diverse experimental conditions?

When interpreting variations in PST1/ST8SIA4 antibody signals across different experimental conditions, researchers should consider:

• Biological versus technical variability assessment:

  • Use technical replicates to establish assay reproducibility

  • Calculate coefficient of variation across replicates (<15% is generally acceptable)

  • Implement statistical approaches appropriate for the experimental design

• Normalization strategies:

  • For Western blots: Normalize to stable housekeeping proteins (β-actin, GAPDH)

  • For IHC: Consider positive cell percentage and staining intensity (H-score)

  • For flow cytometry: Use mean fluorescence intensity (MFI) ratios to isotype controls

• Threshold determination:

  • Establish signal threshold using negative controls

  • Apply consistent quantification criteria across all experimental conditions

  • Consider using receiver operating characteristic (ROC) curves for diagnostic applications

• Comparative analysis framework:

  • Compare relative rather than absolute expression changes between conditions

  • Use fold-change calculations with appropriate statistical tests

  • Consider biological significance thresholds beyond statistical significance

• Common interpretation pitfalls to avoid:

  • Misinterpreting antibody signal intensity as directly proportional to protein abundance

  • Failing to account for post-translational modifications affecting epitope accessibility

  • Overlooking the impact of sample processing variations on signal intensity

  • Comparing results from different antibody lots without validation

• Correlation with functional outcomes:

  • Link PST1 expression changes to functional consequences (e.g., polysialic acid levels)

  • Validate findings with orthogonal methods (RT-qPCR, mass spectrometry)

  • Consider the biological context when interpreting expression changes

What statistical approaches are recommended for quantifying PST1 expression in comparative studies?

For robust quantification of PST1/ST8SIA4 expression in comparative studies, these statistical approaches are recommended:

• Preliminary data assessment:

  • Test for normality using Shapiro-Wilk or Kolmogorov-Smirnov tests

  • Assess homogeneity of variance using Levene's test

  • Identify and handle outliers (using Z-scores or box plot methods)

• For Western blot densitometry:

  • Use integrated optical density (IOD) measurements

  • Apply ANOVA with post-hoc tests for multiple group comparisons

  • Use linear mixed models for repeated measures designs

  • Apply non-parametric alternatives (Mann-Whitney U, Kruskal-Wallis) for non-normal data

• For immunohistochemistry quantification:

  • H-score calculation: ∑(0×% negative cells + 1×% weak positive + 2×% moderate positive + 3×% strong positive)

  • QuickScore: combines intensity (0-3) and proportion scores (1-6)

  • Digital image analysis using machine learning algorithms for unbiased assessment

• For flow cytometry data:

  • Compare mean/median fluorescence intensity (MFI) ratios

  • Use Overton subtraction method for analyzing shifts in populations

  • Apply probability binning for detecting subtle differences between samples

• Sample size and power considerations:

  • Conduct a priori power analysis to determine adequate sample size

  • For pilot studies, consider at least 5-10 samples per group

  • For clinical studies, power calculations typically aim for 80-90% power

• Advanced statistical approaches:

  • ANCOVA to adjust for covariates

  • Multivariate analysis to examine relationships between PST1 and other markers

  • Hierarchical clustering for pattern identification across multiple markers

  • Survival analysis (Kaplan-Meier, Cox regression) for prognostic studies

How can PST1 antibodies be used in single-cell analysis techniques?

PST1/ST8SIA4 antibodies can be integrated into single-cell analytical approaches through these methodological strategies:

• Single-cell protein profiling:

  • Mass cytometry (CyTOF) with metal-conjugated PST1 antibodies

  • Single-cell Western blotting for quantifying protein at individual cell level

  • Imaging mass cytometry for spatial context within tissues

• Multi-omics integration:

  • CITE-seq or REAP-seq combining antibody detection with transcriptomics

  • Correlate PST1 protein levels with ST8SIA4 mRNA expression in the same cells

  • Integrate with single-cell glycomics data for comprehensive pathway analysis

• Spatial transcriptomics correlation:

  • Combine PST1 immunofluorescence with in situ RNA detection

  • Use sequential immunofluorescence and RNA fluorescence in situ hybridization

  • Correlate protein localization with transcriptional activity

• High-dimensional imaging:

  • Imaging mass cytometry for simultaneous detection of >40 markers

  • Cyclic immunofluorescence for sequential staining of multiple markers

  • Co-detection by indexing (CODEX) for highly multiplexed tissue imaging

• Microfluidic approaches:

  • Droplet-based single-cell protein analysis with PST1 antibodies

  • Microfluidic Western blotting for protein isoform analysis

  • Lab-on-a-chip devices for integrated cell isolation and analysis

• Data analysis considerations:

  • Dimensionality reduction techniques (tSNE, UMAP) for visualizing complex datasets

  • Clustering algorithms to identify distinct cell populations

  • Trajectory inference methods to map developmental or disease progressions

What role might PST1 antibodies play in developing therapeutic strategies targeting glycosylation pathways?

PST1/ST8SIA4 antibodies can contribute to therapeutic development targeting glycosylation pathways through:

• Target validation approaches:

  • Confirm ST8SIA4 expression in disease-relevant tissues

  • Correlate expression with disease progression or severity

  • Establish causal relationships through functional studies

• Biomarker development:

  • Use standardized immunoassays to quantify ST8SIA4 in patient samples

  • Develop companion diagnostics for therapies targeting this pathway

  • Stratify patients based on expression levels for clinical trials

• Therapeutic antibody development:

  • Generate function-blocking antibodies targeting ST8SIA4 enzymatic activity

  • Develop antibody-drug conjugates for targeted delivery to ST8SIA4-expressing cells

  • Create bispecific antibodies linking immune cells to ST8SIA4-expressing targets

• Response monitoring strategies:

  • Track changes in ST8SIA4 expression during treatment

  • Correlate with polysialic acid levels and functional outcomes

  • Identify resistance mechanisms through expression analysis

• Investigation of PST1-related pathways in immune regulation:

  • Study potential applications in immune checkpoint modulation

  • Investigate role in immune cell trafficking and function

  • Explore connections to immunotherapy response

• Emerging applications in neurodegenerative diseases:

  • Investigate ST8SIA4 dysregulation in neurodegeneration

  • Develop strategies to restore appropriate polysialylation

  • Target specific neural circuits through ST8SIA4-mediated approaches